Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956135912> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2956135912 endingPage "3825" @default.
- W2956135912 startingPage "3825" @default.
- W2956135912 abstract "Abstract Addition of CDK4/6 inhibitors such as palbociclib, ribociclib or abemaciclib to endocrine-based therapies significantly improves progression-free and in some subgroups, overall survival in patients with advanced estrogen receptor-positive (ER+) breast cancer. However, acquired resistance to CDK4/6 inhibitors remains a significant unmet clinical need. It is critical to ascertain the mechanisms by which tumor cells evade CDK4/6 based therapy. In this study we screen multiple in vitro and in vivo models of acquired resistance to CDK4/6 inhibitors to identify potential resistance/escape pathways and targets for pharmaceutical intervention to overcome resistance. ER+ breast cancer cell lines of diverse molecular backgrounds were conditioned to acquire resistance to CDK4/6 inhibitors through either long-term culture in the presence of clinically relevant concentrations of inhibitors or as cell line xenografts treated through progression on a CDK4/6 inhibitor plus fulvestrant. Baseline and pharmacodynamic changes in cell signaling were measured using reverse phase protein array (RPPA) and RNAseq analysis. Acquired resistance to CDK4/6 inhibitors was associated with decreases in phosphorylated-Rb (pRb) and ER-alpha protein and increases in pAKT and pS6 relative to isogenic controls. The p110α-selective PI3K-inhibitor, alpelisib, in combination with fulvestrant or ribociclib/fulvestrant blocked pAKT signaling in xenografts progressing on palbociclib/fulvestrant and induced significant tumor regressions. Apelisib plus fulvestrant also produced robust anti-tumor responses in xenografts progressing on ribociclib/fulvestrant. Triple combination treatment with ribociclib/alpelisib/fulvestrant induced significant regressions in resistant tumors and in treatment naïve models, where complete tumor regressions occurred regardless of PIK3CA mutation status. Regressions were maintained for >9 weeks post withdrawal of treatment, indicating that therapeutic resistance may be prevented by this triple combination approach. RPPA analysis of responding tumors identified sustained inhibition of both PI3K- and CDK4/6:Rb-pathway signaling accompanied by activation of pro-apoptotic proteins. These data support clinical investigation of targeting PI3K with alpelisib in breast cancers progressing on CDK4/6 based therapies and investigation of upfront triple combination therapy prior to acquisition of resistance to CDK4/6. Citation Format: Neil A. O'Brien, Martina SJ McDermott, Dylan F. Conklin, Alex Gaither, Tong Luo, Raul Ayala, Suruchi Salgar, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon. Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3825." @default.
- W2956135912 created "2019-07-12" @default.
- W2956135912 creator A5000509598 @default.
- W2956135912 creator A5001570411 @default.
- W2956135912 creator A5005415248 @default.
- W2956135912 creator A5015491002 @default.
- W2956135912 creator A5028010756 @default.
- W2956135912 creator A5032160958 @default.
- W2956135912 creator A5034763642 @default.
- W2956135912 creator A5039664664 @default.
- W2956135912 creator A5040584710 @default.
- W2956135912 creator A5045387212 @default.
- W2956135912 creator A5046772134 @default.
- W2956135912 creator A5054927824 @default.
- W2956135912 creator A5064586606 @default.
- W2956135912 creator A5068059897 @default.
- W2956135912 creator A5080632946 @default.
- W2956135912 date "2019-07-01" @default.
- W2956135912 modified "2023-10-05" @default.
- W2956135912 title "Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models" @default.
- W2956135912 doi "https://doi.org/10.1158/1538-7445.am2019-3825" @default.
- W2956135912 hasPublicationYear "2019" @default.
- W2956135912 type Work @default.
- W2956135912 sameAs 2956135912 @default.
- W2956135912 citedByCount "2" @default.
- W2956135912 countsByYear W29561359122020 @default.
- W2956135912 crossrefType "journal-article" @default.
- W2956135912 hasAuthorship W2956135912A5000509598 @default.
- W2956135912 hasAuthorship W2956135912A5001570411 @default.
- W2956135912 hasAuthorship W2956135912A5005415248 @default.
- W2956135912 hasAuthorship W2956135912A5015491002 @default.
- W2956135912 hasAuthorship W2956135912A5028010756 @default.
- W2956135912 hasAuthorship W2956135912A5032160958 @default.
- W2956135912 hasAuthorship W2956135912A5034763642 @default.
- W2956135912 hasAuthorship W2956135912A5039664664 @default.
- W2956135912 hasAuthorship W2956135912A5040584710 @default.
- W2956135912 hasAuthorship W2956135912A5045387212 @default.
- W2956135912 hasAuthorship W2956135912A5046772134 @default.
- W2956135912 hasAuthorship W2956135912A5054927824 @default.
- W2956135912 hasAuthorship W2956135912A5064586606 @default.
- W2956135912 hasAuthorship W2956135912A5068059897 @default.
- W2956135912 hasAuthorship W2956135912A5080632946 @default.
- W2956135912 hasConcept C121608353 @default.
- W2956135912 hasConcept C126322002 @default.
- W2956135912 hasConcept C143998085 @default.
- W2956135912 hasConcept C2775930923 @default.
- W2956135912 hasConcept C2779744173 @default.
- W2956135912 hasConcept C2780482068 @default.
- W2956135912 hasConcept C502942594 @default.
- W2956135912 hasConcept C530470458 @default.
- W2956135912 hasConcept C55493867 @default.
- W2956135912 hasConcept C62478195 @default.
- W2956135912 hasConcept C71924100 @default.
- W2956135912 hasConcept C84606932 @default.
- W2956135912 hasConcept C86554907 @default.
- W2956135912 hasConcept C86803240 @default.
- W2956135912 hasConcept C98274493 @default.
- W2956135912 hasConceptScore W2956135912C121608353 @default.
- W2956135912 hasConceptScore W2956135912C126322002 @default.
- W2956135912 hasConceptScore W2956135912C143998085 @default.
- W2956135912 hasConceptScore W2956135912C2775930923 @default.
- W2956135912 hasConceptScore W2956135912C2779744173 @default.
- W2956135912 hasConceptScore W2956135912C2780482068 @default.
- W2956135912 hasConceptScore W2956135912C502942594 @default.
- W2956135912 hasConceptScore W2956135912C530470458 @default.
- W2956135912 hasConceptScore W2956135912C55493867 @default.
- W2956135912 hasConceptScore W2956135912C62478195 @default.
- W2956135912 hasConceptScore W2956135912C71924100 @default.
- W2956135912 hasConceptScore W2956135912C84606932 @default.
- W2956135912 hasConceptScore W2956135912C86554907 @default.
- W2956135912 hasConceptScore W2956135912C86803240 @default.
- W2956135912 hasConceptScore W2956135912C98274493 @default.
- W2956135912 hasIssue "13_Supplement" @default.
- W2956135912 hasLocation W29561359121 @default.
- W2956135912 hasOpenAccess W2956135912 @default.
- W2956135912 hasPrimaryLocation W29561359121 @default.
- W2956135912 hasRelatedWork W2887764714 @default.
- W2956135912 hasRelatedWork W2921920460 @default.
- W2956135912 hasRelatedWork W2931385471 @default.
- W2956135912 hasRelatedWork W3083148719 @default.
- W2956135912 hasRelatedWork W3093743109 @default.
- W2956135912 hasRelatedWork W3203690439 @default.
- W2956135912 hasRelatedWork W4206711305 @default.
- W2956135912 hasRelatedWork W4248789801 @default.
- W2956135912 hasRelatedWork W4322772104 @default.
- W2956135912 hasRelatedWork W4386328992 @default.
- W2956135912 hasVolume "79" @default.
- W2956135912 isParatext "false" @default.
- W2956135912 isRetracted "false" @default.
- W2956135912 magId "2956135912" @default.
- W2956135912 workType "article" @default.